ASH Global Perspectives | Prof. Wojciech Jurczak: First Results of BRUIN CLL-313 Suggest Non-Covalent BTK Inhibitors May Reshape First-Line CLL/SLL Treatment

ASH Global Perspectives | Prof. Wojciech Jurczak: First Results of BRUIN CLL-313 Suggest Non-Covalent BTK Inhibitors May Reshape First-Line CLL/SLL Treatment

2026.01.16
Chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL) is a clonal proliferative disorder of mature B cells that predominantly affects older adults and is characterized by a distinctive immunophenotype. At the Late-Breaking Abstract (LBA) session of the 2025 American Society of Hematology (ASH) Annual Meeting, Professor Wojciech Jurczak from the Maria Skłodowska-Curie National Research Institute of Oncology presented the first results of the BRUIN CLL-313 study. This randomized phase III trial compared the efficacy and safety of the non-covalent BTK inhibitor pirtobrutinib with bendamustine plus rituximab (BR) in treatment-naïve patients with CLL/SLL. On-site, Oncology Frontier – Hematology Frontier invited Professor Jurczak to provide insights into the study background, design, and clinical implications, offering forward-looking guidance for clinical practice.
2025 Tianjin International Breast Cancer Conference |Professor Zhang Juliang: Skip the “Grand Narrative”—Even Small Questions Can Lead to Big Papers! Expert Advice on How Early- and Mid-Career Doctors Can Break Through With IITs

2025 Tianjin International Breast Cancer Conference |Professor Zhang Juliang: Skip the “Grand Narrative”—Even Small Questions Can Lead to Big Papers! Expert Advice on How Early- and Mid-Career Doctors Can Break Through With IITs

2026.01.13
From “following evidence” to “creating evidence”, clinical research in breast cancer in China is entering a deep phase of high-quality development. Within the grand framework of precision medicine, industry-sponsored trials (ISTs) may serve as the gateway for innovative drugs to enter clinical practice, but investigator-initiated trials (IITs) are the master key to solving the “last mile” problems of real-world clinical application.
SABCS Expert Commentary | Professor Jin Feng: Reanalysis of the Landmark NSABP B-20 Trial—Can MMAI Become a Low-Cost Option for Risk Stratification?

SABCS Expert Commentary | Professor Jin Feng: Reanalysis of the Landmark NSABP B-20 Trial—Can MMAI Become a Low-Cost Option for Risk Stratification?

2026.01.13
At the 2025 San Antonio Breast Cancer Symposium (SABCS 2025), a reanalysis of the landmark NSABP B-20 trial (Abstract No. RF3-03) was presented, exploring the prognostic value and chemotherapy benefit–predictive potential of a multimodal artificial intelligence (MMAI) model based on digital pathology and clinical data in hormone receptor–positive (HR+), node-negative early breast cancer.
SABCS Expert Commentary |Professor Jin Feng: Deep Learning Accurately Predicts Late Distant Metastasis in HR-Positive Early Breast Cancer and Guides Decisions on Extended Endocrine Therapy

SABCS Expert Commentary |Professor Jin Feng: Deep Learning Accurately Predicts Late Distant Metastasis in HR-Positive Early Breast Cancer and Guides Decisions on Extended Endocrine Therapy

2026.01.13
At the 2025 San Antonio Breast Cancer Symposium (SABCS 2025), a study based on data from the NSABP B-42 and TAILORx trials (Abstract No. RF3-07) reported the development and validation of a multimodal, multitask deep learning model (Clarity BCR). By integrating routine digital pathology images with key clinical variables, this model accurately predicts the risk of late distant recurrence (late DR) in patients with hormone receptor–positive (HR+) early breast cancer and effectively identifies those who may benefit from extended endocrine therapy (EET).
SABCS Expert Commentary |Professor Jin Feng: New Evidence for Precision Immunotherapy in Early Triple-Negative Breast Cancer—Gene Expression Subtyping Predicts Response to Neoadjuvant Immunochemotherapy

SABCS Expert Commentary |Professor Jin Feng: New Evidence for Precision Immunotherapy in Early Triple-Negative Breast Cancer—Gene Expression Subtyping Predicts Response to Neoadjuvant Immunochemotherapy

2026.01.13
At the 2025 San Antonio Breast Cancer Symposium (SABCS 2025), a study titled “Gene Expression-based Subtyping of Early Triple-Negative Breast Cancer for Prediction of Response to Neoadjuvant Immune-chemotherapy in the NSABP B-59/GBG-96-GeparDouze Trial” (Abstract No. RF3-02) was presented. The study provides an in-depth analysis of the heterogeneity of benefit from immunotherapy in early triple-negative breast cancer (TNBC), revealing the predictive value of tumor-infiltrating lymphocytes (TILs) and molecular TNBC subtypes for treatment efficacy.
SABCS Expert Commentary | Professor Mao Xiaoyun: The ALTTO Study Confirms Superior DFS With Aromatase Inhibitors Over SERMs, Providing New Evidence for Endocrine Therapy in HR+/HER2+ Breast Cancer

SABCS Expert Commentary | Professor Mao Xiaoyun: The ALTTO Study Confirms Superior DFS With Aromatase Inhibitors Over SERMs, Providing New Evidence for Endocrine Therapy in HR+/HER2+ Breast Cancer

2026.01.13
In patients with HR-positive/HER2-positive early breast cancer, adjuvant anti-HER2 therapy constitutes the cornerstone of systemic treatment. However, robust high-level evidence has long been lacking to guide the choice between aromatase inhibitors (AIs) and tamoxifen (SERMs) for adjuvant endocrine therapy in this population.